Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.

× No keyword cloud information.

11 in total

1. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Authors: Nesrine Boukhedouni; Christina Martins; Anne-Sophie Darrigade; Claire Drullion; Jérôme Rambert; Christine Barrault; Julien Garnier; Clément Jacquemin; Denis Thiolat; Fabienne Lucchese; Franck Morel; Khaled Ezzedine; Alain Taieb; François-Xavier Bernard; Julien Seneschal; Katia Boniface
Journal: JCI Insight Date: 2020-06-04

Review 2. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.

Authors: Christopher White; Richard Miller
Journal: J Clin Aesthet Dermatol Date: 2022-04

Review 3. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors: Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal: Dermatol Ther (Heidelb) Date: 2019-10-13

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.

1. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Review 2. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.

Review 3. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Review 4. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.

Review 5. Vitiligo, From Physiopathology to Emerging Treatments: A Review.

6. Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response.

Review 7. The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.

Review 8. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.

9. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

10. Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).